Literature DB >> 10378884

T-cell tumor necrosis factor-alpha receptor binding in myasthenic patients.

P Bongioanni1, R Ricciardi, D Pellegrino, M R Romano.   

Abstract

Myasthenia gravis (MG) is a T-cell-dependent and antibody-mediated autoimmune disease of the neuromuscular junction, in which the cytokine network may be deranged. Specific receptors for tumor necrosis factor (TNF)-alpha, a cytokine with several effects on the neuroimmune system, were found on human lymphocytes. In the present study, we assayed TNF-alpha binding on peripheral blood T-cells from MG patients, finding that T-cells from patients have significantly more TNF-alpha receptors than those from controls (Bmax: 654 +/- 12 vs. 133 +/- 4 (mean +/- SEM) receptors/cell). Such TNF-alpha binding sites are of the same type in patients and healthy subjects (Kd: 68.7 +/- 4.3 vs. 70.1 +/- 4.8 (mean +/- SEM) pM). The enhanced T-cell TNF-alpha binding is due to an increased number of TNF-alpha receptors on T-helper lymphocytes. These results are discussed in terms of MG immunopathogenesis, since it has been reported that activated T-cells have increased amounts of TNF-alpha receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10378884     DOI: 10.1016/s0165-5728(98)00235-5

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  2 in total

Review 1.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

Review 2.  Targeting Regulatory T Cells by Addressing Tumor Necrosis Factor and Its Receptors in Allogeneic Hematopoietic Cell Transplantation and Cancer.

Authors:  Harald Wajant; Andreas Beilhack
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.